Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06415760 · ClinicalTrials.gov registry record
Reference Range Study for the Quantra System With the QStat Cartridge in Obstetric Patients
A clinical trial, sponsored by HemoSonics.
- Completed
- Registry status
- 129
- Enrollment target
NCT06415760: Completed study, sponsored by HemoSonics.
NCT06415760 is a clinical trial that has completed, run by HemoSonics. The registered enrollment target is 129 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06415760 has completed, sponsored by HemoSonics.
- COMPLETED
- Registry status
- 129 participants
- Enrollment target
Study Summary
This study will determine reference range intervals for the parameters reported by the Quantra System with the QStat Cartridge in the last trimester of non-laboring pregnant women with an uncomplicated pregnancy
Primary Outcome
Reference range intervals for CSL for pregnant women in third trimester
Interventions
- DIAGNOSTIC_TEST Quantra System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2024-05-07 |
| Est. Completion | 2025-07-01 |
What the finished NCT06415760 record still lists
NCT06415760 is an observational study that tracks outcomes without assigning an intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Quantra System is the first listed.
NCT06415760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06415760 about?
NCT06415760 is a clinical study titled "Reference Range Study for the Quantra System With the QStat Cartridge in Obstetric Patients". This study will determine reference range intervals for the parameters reported by the Quantra System with the QStat Cartridge in the last trimester of non-laboring pregnant women with an uncomplicated pregnancy
What is the current status of trial NCT06415760?
This trial is currently completed. The enrollment target is 129 participants. The study started on 2024-05-07. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT06415760?
The interventions under investigation include: Quantra System (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06415760?
This trial is sponsored by HemoSonics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI